A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily

Trial Profile

A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms CONFIDENCE
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 09 Aug 2017 This trial has been completed in Finland (End date:2017-06-02) according to European Clinical Trials Database record .
    • 25 Jul 2017 This trial has been completed Poland (End date:2017-06-02).
    • 28 Jun 2017 This trial has been completed in Spain (End date:2017-06-02).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top